# 14th International Conference on Thalassaemia & Haemoglobinopathies

### 17 - 19 November 2017

## Thessaloniki, Greece

## Friday 17th November 2017 // Hall TBC

#### **OPENING CEREMONY**

#### Master of Ceremonies:

18.00 – 19.00 Opening remarks

19.00 – 19.15 TIF Award Ceremony

#### **KEYNOTE PRESENTATIONS**

Chairpersons: C. Kattamis & D. Loukopoulos

19.15 – 19.30 Haemoglobinopathies Care & Cure: Have we reached the end? – J. Porter

19.30 – 19.45 Migration: The aftershocks to the provision of healthcare – S. Lobitz

19.45 – 20.00 Patients' as Equal Partners in Decision-Making: The Global Reality

## Saturday 18th November 2017 // Olympia B Hall

08.45 – 10.15	Session 1: Diagnosis & Prevention Chairpersons: J. Synodinou
08.45 - 09.00	Diagnosis of Haemoglobinopathies: New scientific advances – C.L. Harteveld
09.00 - 09.15	New Challenges in diagnosis of haemoglobinopathies: Migration of Populations – J. Old
09.15 - 09.30	Global Overview of Neonatal Screening Practices of Haemoglobinopathies – S. Lobitz
09.30 - 09.45	Informed choice in a multicultural world – M. Petrou

09.45 – 10.00	Diagnostic strategies on hemoglobinopathy testing, the role of a reference laboratory in the USA
10.00 – 10.15	Discussion
10.15 – 11.30	Session 2: Cornerstones of Clinical Management of Haemoglobinopathies Chairpersons:
10.15 – 10.30	Optimal Blood Transfusion Therapy in Haemoglobinopathies – J. Porter
10.30 – 10.45	Iron Overload & Chelation in Haemoglobinopathies – A. Taher
10.45 – 11.00	Multidisciplinary Care: the UK Experience – P. Eleftheriou
11.00 – 11.15	Best practices in assessing iron overload today: A need for Guidelines? - V. Viprakasit
11.15 – 11.30	Discussion
11.30 – 13.00	Session 3: Managing Complications in Haemoglobin Disorders – New Advances (I) Chairpersons:
11.30 – 11.50	Endocrine complications – V. de Sanctis
11.50 – 12.10	Cardiac complications – M. Walker
12.10 – 12.30	Liver complications
12.30 – 12.50	Renal complications – A. Taher
12.50 – 13.00	Discussion
13.00 – 13.45	Session 4: Haemoglobinopathies in Focus: Sickle Cell Disease Chairpersons: A. Taher
13.00 – 13.15	Clinical Management of Sickle Cell Disease in Childhood & Adolescence – M. Abboud
13.15 – 13.30	Clinical Management of Sickle Cell Disease in Adulthood
13.30 – 13.45	Discussion
13.45 – 15.15	SATELLITE SESSION 1
15.15 – 16.15	Session 5: Challenges in Delivering Treatment Chairpersons:
15.15 – 15.30	National policies in ensuring access to quality & safety of drugs: A challenge or a prerequisite – <i>M. Hadipour</i>
15.30 – 16.00	Adherence to Treatment: Doctor vs Patient Perspective – F. Shah & TBC

16.00 – 16.15	Patient care: Unmet needs globally – M. Angastiniotis
16.15 – 17.15	Session 6: Improving quality healthcare – Networks & Accreditation Panellists: M. Angastiniotis, L. Brunetta, G. Constantinou, P. Eleftheriou, S. Fucharoen & A. Taher
16.15 – 16.30	The EUROBLOODNET Experience
16.30 – 16.45	Global initiatives for improving quality healthcare by the Thalassaemia International Federation – <i>A. Eleftheriou</i>
16.45 – 17.15	Panel Discussion – Challenges in securing quality healthcare services for haemoglobinopathy patients
17.15 – 18.45	SATELLITE SESSION 2

Sunday 19th	November 2017
-------------	---------------

08.30- 09.30	Oral Presentations			
Hall 1 – Olympia E	Hall 2 – V. Patoulidou	Hall 3 – Ilida	Hall 3 – Kallipateira	
Topics to be announced	Topics to be announced	Topics to be announced	Topics to be announced	
Plenary Sessions: Olympia B Hall				
09.30 - 10.30	Session 7: Managing Complications in Haemoglobin Disorders – New Advances (II)			
	Chairpersons:			
09.30 - 09.50	Osteoporosis – E. Voskaridou			
09.50 – 10.10	Pain: Time for more action?			
10.10 – 10.20	The role of CNS in the care of haemoglobinopathy patients – B. Hylton			
10.20 – 10.30	Discussion			
10.30 – 11.00	Session 8: Quality of Life in Patients with Haemoglobin Disorders Chairpersons: R. Elbard & G. Theophanous			
10.30 – 10.40	Quality of Life: Transfusion D Thalassaemia – <i>M. Karimi</i>	ependent Thalassaemia <i>v</i> s	Non-Transfusion Dependent	

10.40 – 10.50	Moving towards Patient Reported Outcomes – V. Viprakasit
10.50 – 11.00	Discussion
11.15 – 12.45	Session 9: New Advances in Haemoglobinopathies Chairpersons: D. Kountouras & E. Yannaki
11.15 – 11.45	The changing face of Management: Latest update of on-going clinical trials – A Piga
11.45 – 12.00	Advances in Gene Therapy Trials
12.00 – 12.15	Treatment of Liver Disease: New developments
12.15 – 12.30	Gene Editing – B. Lundberg
12.30 – 12.50	TBC
12.50 – 13.00	Discussion
13.00 – 13.15	Closing remarks P. Englezos, V. Dimos, C. Papageorgiou, S. Tuli, R. Ficarra
13.15 – 14.00	LUNCH